Medical Device News Magazine

ImmunoCAP Specific IgE alpha-Gal Allergen Component Test Receives FDA Clearance

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

ImmunoCAP Specific IgE alpha-Gal Allergen Component Test has received U.S. Food & Drug Administration (FDA)Clearance for in vitro diagnostic use.. The news was announced today by Thermo Fischer Scientific.

According to the American Academy of Asthma, Allergy and Immunology, an allergy to alpha-Gal can cause patients to have a severe and potentially life-threatening reaction to galactose-alpha-1, 3-galactose that is found in most mammalian (red) meat. Unlike other food allergies, reactions from eating red meat may be delayed, occurring three to eight hours after eating. Symptoms range from hives and itching, to abdominal pain, nausea or vomiting. In severe cases the allergy can cause anaphylaxis which can be potentially fatal. The condition can appear in patients who have tolerated meat for many years, with researchers believing that sensitization to alpha-Gal may be the result of a bite from the lone star tick (Amblyomma americanum).

“Alpha-gal is dramatically different from other forms of food allergy,” said Thomas Platts-Mills, MD, professor of medicine and microbiology at the University of Virginia School of Medicine and a leading researcher on the topic. “Previously healthy adults can suddenly develop potentially life-threatening reactions to red meats such as beef, pork and lamb. The delayed nature of the reactions adds to the difficulty that clinicians and patients have in identifying the cause of the symptoms. This unique set of circumstances makes an accurate diagnosis critical for managing this disease.”

ImmunoCAP Specific IgE alpha-Gal Allergen Component Test is the most widely used specific IgE blood test, and its use is documented in more than 6,000 peer-reviewed publications. The tests can help identify allergic sensitization to common environmental allergens – seasonal and perennial, outdoor and indoor– as well as common food allergens such as peanut, egg and milk. The ImmunoCAP Specific IgE Stinging Insect Allergen Component tests were recently cleared by the FDA to help improve the diagnosis of bee and wasp allergies. ImmunoCAP Specific IgE blood tests, which are available in most major U.S. laboratories, can be ordered for patients of any age regardless of skin condition, current medication, disease activity or pregnancy status.

“Sensitization to the alpha-Gal carbohydrate has been notoriously difficult to measure in patients,” said Dr. Lakiea Wright, MD MAT MPH, Medical Director, US ImmunoDiagnostics at Thermo Fisher Scientific. “Skin prick testing to red meats such as beef, pork, or lamb often gives weak or negative results, which is why, based on clinical studies, quantification of IgE antibodies to alpha-Gal in the blood is the preferred diagnostic method. Information from these tests can help providers be more precise in their diagnosis and management recommendations.”

 

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”